Eris Lifesciences Ltd vs Marksans Pharma Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 09, 2026

Key Highlights

The Latest Trading Price of ERIS Lifesciences Ltd is ₹ 1386 as of 08 May 15:30 . The P/E Ratio of ERIS Lifesciences Ltd changed from 23.1 on March 2021 to 54.8 on March 2025 . This represents a CAGR of 18.86% over 5 yearsThe P/E Ratio of Marksans Pharma Ltd changed from 8.7 on March 2021 to 26.5 on March 2025 . This represents a CAGR of 24.95% over 5 years The Market Cap of ERIS Lifesciences Ltd changed from ₹ 8207 crore on March 2021 to ₹ 19287 crore on March 2025 . This represents a CAGR of 18.64% over 5 yearsThe Market Cap of Marksans Pharma Ltd changed from ₹ 2044 crore on March 2021 to ₹ 10076 crore on March 2025 . This represents a CAGR of 37.58% over 5 years The revenue of ERIS Lifesciences Ltd for the Dec '25 is ₹ 807.59 crore as compare to the Sep '25 revenue of ₹ 795.5 crore. This represent the growth of 1.52% The revenue of Marksans Pharma Ltd for the Dec '25 is ₹ 774.57 crore as compare to the Sep '25 revenue of ₹ 741.98 crore. This represent the growth of 4.39% The ebitda of ERIS Lifesciences Ltd for the Dec '25 is ₹ 264.51 crore as compare to the Sep '25 ebitda of ₹ 291.3 crore. This represent the decline of -9.2% The ebitda of Marksans Pharma Ltd for the Dec '25 is ₹ 180.89 crore as compare to the Sep '25 ebitda of ₹ 166.07 crore. This represent the growth of 8.92% The net profit of ERIS Lifesciences Ltd changed from ₹ 89.55 crore to ₹ 108.83 crore over 7 quarters. This represents a CAGR of 11.79% The net profit of Marksans Pharma Ltd changed from ₹ 89.07 crore to ₹ 113.69 crore over 7 quarters. This represents a CAGR of 14.97% The Dividend Payout of ERIS Lifesciences Ltd changed from 21.3 % on March 2021 to 129.35 % on March 2025 . This represents a CAGR of 43.44% over 5 yearsThe Dividend Payout of Marksans Pharma Ltd changed from 10.4 % on March 2021 to 19.26 % on March 2025 . This represents a CAGR of 13.12% over 5 years .

About ERIS Lifesciences Ltd

Eris Lifesciences Limited was incorporated on January 25, 2007.
Subsequently, the name of the company was changed to 'Eris Lifesciences Private Limited' on February 9, 2007.
Further, the Company was converted into a Public Limited cCompany and the name was changed to 'Eris Lifesciences Limited' on February 2, 2017.
The Company has a manufacturing plant in Guwahati, Assam and is presently engaged in manufacturing and marketing of pharmaceutical products.
It has presence in high growth chronic, sub chronic and acute therapeutic areas that require high intervention of specialist and super specialist doctors. The company develops, manufactures and commercializes branded pharmaceutical products in selected therapeutic areas within chronic and acute categories of the Indian Pharmaceutical Market (IPM), such as: cardiovascular; anti-diabetics; vitamins; gastroenterology; and anti-infective.

About Marksans Pharma Ltd

Marksans Pharma Limited was formerly incorporated as 'Tasc Pharmaceuticals Limited' in April, 1982.
Pursuant to the Scheme of Amalgamation, name of the Company was changed from Tasc Pharmaceuticals Limited to Marksans Pharma Limited from 10th October, 2005.
The Company primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulation.
The Company's research and development facilities are located in Verna, Goa and R & D center in Navi Mumbai. In 2004-05, the Company amalgamated with M/s.
Marksans Pharma Limited (formerly M/s.

FAQs for the comparison of ERIS Lifesciences Ltd and Marksans Pharma Ltd

Which company has a larger market capitalization, ERIS Lifesciences Ltd or Marksans Pharma Ltd?

Market cap of ERIS Lifesciences Ltd is 19,212 Cr while Market cap of Marksans Pharma Ltd is 8,968 Cr

What are the key factors driving the stock performance of ERIS Lifesciences Ltd and Marksans Pharma Ltd?

The stock performance of ERIS Lifesciences Ltd and Marksans Pharma Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for ERIS Lifesciences Ltd and Marksans Pharma Ltd?

As of May 9, 2026, the ERIS Lifesciences Ltd stock price is INR ₹1386.75. On the other hand, Marksans Pharma Ltd stock price is INR ₹197.9.

How do dividend payouts of ERIS Lifesciences Ltd and Marksans Pharma Ltd compare?

To compare the dividend payouts of ERIS Lifesciences Ltd and Marksans Pharma Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.